VeriStrat test for benefit w/oral EGFR inhibitors launched by Biodesix; would prefer that proponent experts not have financial stake in it.

I don't think that maintenance tarceva results to be shown at ASCOwill have an earth-shattering effect on treatment patterns for adv NSCLC.

Saw CTIC ticker: Good news for company: always nice to double your stock value in a day. Bad news: you can do that with a 64 cent run-up.

Happy to visit NYC, but leaving after 16 hours ground makes it really not worth the flights to & from Seattle. Hope the meeting is good...

Just reviewed ASCO abstracts. It's clear that reporting only "hazard ratio" w/o absolute #s is a way to obscure underwhelming results.

Sad to see pharma companies in bitter divorce lawsuit, arguing over who gets which asset: http://tinyurl.com/OnyxvBayer

Interesting & sad 2 see ASCO exhibits now empty once pens and notepads no longer given away. Speaks poorly 4 oncs & bad omen for ASCO $$.

ASCO was notably low energy & smaller crowds this yr. I think virtual ASCO & local ASCO highlights mtgs will lead 2 smaller ASCO over time.

Flying SWA: outlets & USB charges provided at gate, so diff from most carriers & HUGE way to appeal to road warriors. Others should as well.

Another day, another press release from CTI: http://bit.ly/Y6LA0 -- I think it's more newsworthy when CTI DOESN'T submit a press release.

Most of my tweets are from another acct, @DrWestGRACE; rec folks follow that if not already. This acct is more for back end pharma thoughts.

I nominate GRACE for a Shorty Award in #nonprofit because they provide incredibly helpful information to cancer patients & caregivers